Effects of Myo-inositol Plus Melatonin in Perimenopausal Women
试验速览
- 阶段
- 不适用
- 发起方
- 试验地点
- 2
研究概览
简要总结
Menopause is the milestone of a more broaden condition that can last up to 10 years. The first menopausal symptoms usually appear around the age of 42 and are characterized by a gradual decline in thyroid and gonadal function with a progressive increase of plasmatic luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels.
Recent studies have shown that myo-inositol and melatonin play a major role in ovarian homeostasis. In particular, it has been demonstrated that myo-inositol and/or melatonin supplementation lead to an increase of oocyte quality.
Additional studies focused on postmenopausal women have shown that myo-inositol is able to ameliorate the metabolic syndrome that often affects these patients, thus reducing the risk of cardiovascular diseases (CVDs).
The aim of the present study is to evaluate whether myo-inositol and melatonin might play a positive role in regulating hormonal levels during menopausal onset.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 42 Years 至 48 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •FSH between 15 and 50 IU/ml on the 5th day of the menses
- •Oligomenorrhea
排除标准
- 未提供
研究组 & 干预措施
Placebo
干预措施: Placebo (Dietary Supplement)
Myo+Mel
Patients are treated with 2g of myo + 3mg of melatonin daily
干预措施: Myo-Mel (Dietary Supplement)